Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a cas...

Full description

Bibliographic Details
Main Authors: Paul V. Viscuse, Mario L. Marques-Piubelli, Meghan M. Heberton, Edwin Roger Parra, Amishi Y. Shah, Arlene Siefker-Radtke, Jianjun Gao, Sangeeta Goswami, Doina Ivan, Jonathan L. Curry, Matthew T. Campbell
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
bladder cancer
enfortumab vedotin
SJS/TEN
urothelial cancer
adverse (side) effects
erythema multiform
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.621591/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.621591/full

Similar Items